- Home
- MYO vs RNXT Comparison
MYO vs RNXT Comparison
Compare MYO & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MYO | RNXT |
|---|---|---|
| Founded | 2004 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.9M | 37.4M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MYO | RNXT |
|---|---|---|
| Price | $0.68 | $0.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $7.67 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 367.8K | 200.6K |
| Earning Date | 06-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.60 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,000,000,000.00 | $43,000.00 |
| Revenue This Year | $24.07 | $2,995.35 |
| Revenue Next Year | $17.48 | $219.61 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 40814.79 | N/A |
| 52 Week Low | $0.64 | $0.70 |
| 52 Week High | $6.27 | $1.45 |
Technical Indicators
Market Signals| Indicator | MYO | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 38.18 | 39.86 |
| Support Level | $0.64 | $0.82 |
| Resistance Level | $1.03 | $1.07 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 23.90 | 24.78 |
Price Performance
Historical ComparisonAbout MYO Myomo Inc.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.